[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362582-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362582-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","influence-of-snvs-on-adverse-reactions-and-survival-in-gefitinib-treated-lung-cancer-patients-a-preliminary-study","Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients - A preliminary study","","Retrospective cohort study assessing whether single-nucleotide variants (SNVs) in EGFR, ABCB1, and ABCG2 affect gefitinib-related adverse drug reactions (ADRs) and survival in non-small cell lung cancer (NSCLC). Patients with EGFR mutations in exons 19, 20, or 21 received gefitinib 250 mg/day. Genotyping used real-time PCR and ADRs were graded per CTCAE v5. ABCB1 rs2032582 non-CC genotype increased diarrhea risk, while the AA genotype increased death risk. Findings require confirmation in larger cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/influence-of-snvs-on-adverse-reactions-and-survival-in-gefitinib-treated-lung-cancer-patients-a-preliminary-study/362582/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/influence-of-snvs-on-adverse-reactions-and-survival-in-gefitinib-treated-lung-cancer-patients-a-preliminary-study/362582.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient group was included in the preliminary study?","Question",{"text":63,"@type":64},"Patients with NSCLC carrying EGFR mutations in exons 19, 20, or 21 who were treated with gefitinib 250 mg/day were included, with genetic analyses performed in 33 patients after exclusions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which genetic variant was linked to higher diarrhea risk?",{"text":68,"@type":64},"ABCB1 rs2032582 non-CC genotype was associated with a higher risk of diarrhea compared with the CC genotype.",{"name":70,"@type":61,"acceptedAnswer":71},"What variant was associated with higher risk of death?",{"text":72,"@type":64},"The ABCB1 AA genotype was associated with a higher risk of death compared with the CA, CCCC/CA/CT, and TT genotypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362582,1790178329,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInfluence ofSNVs on adverse reactions and survival in gefitinibtreated lung cancer patients from a preliminary study  \nMariana Vieira Morau1, Cecília Souto Seguin1, Mauricio Wesley Perroud Jr2,  \nCarolina Dagli-Hernandez3,4, Giovana Fernanda Santos Fidelis1, Eder de Carvalho Pincinato2 & Patricia Moriel3􀀍  \nGefitinib is indicated for metastatic non-small cell lung cancer (NSCLC) with active mutations in the epidermal growth factor receptor (EGFR) gene; however, its use is frequently associated with dermatological, gastrointestinal, and hepatic adverse drug reactions (ADRs). This study investigated whether single-nucleotide variants (SNVs) in the EGFR, ABCB1, and ABCG2 influence gefitinib-related ADRs and survival in patients with NSCLC. This retrospective cohort study included patients with NSCLC harboring EGFR mutations in exons 19, 20, or 21, who were treated with gefitinib (250 mg/ day). Genotyping was performed using real-time PCR, and ADRs were classified according to the Common Terminology Criteria for Adverse Events, version 5. The ABCB1 rs2032582 non-CC genotype was associated with a higher risk of diarrhea (p = 0.0344, OR= 7.579) than the CC genotype. The AA genotype was associated with a higher risk of death (p = 0.0048; HR = 32.498) than the CA, CCCC/CA/CT, and TT genotypes. Our findings suggest that ABCB1 SNVs influence gefitinib-related ADRs and patient survival in NSCLC. However, as this was an exploratory and preliminary study, further investigations with larger and more robust cohorts are essential to confirm and validate these findings.  \nKeywords Pharmacogenetics, Pharmacovigilance, Precision medicine, Antineoplastic agents, ATP-binding cassete transporters (ABC transporters), Lung cancer, Gefitinib  \nNon-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer (LC) cases and is the leading cause of cancer-related deaths worldwide1,2. Smoking is the primary risk factor for LC, although individuals who have never smoked can be diagnosed with cancer based on environmental, behavioral, and genetic factors3. Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, is indicated for advanced stages of metastatic NSCLC with activating EGFR mutations, mainly in exons 19 and 20–21 4.  \nDespite being the first TKI approved by the Food and Drug Administration (FDA) in 2003, gefitinib remains widely used in clinical practice, particularly in developing countries5. It isan orally administered chemotherapeutic drug and is well-tolerated compared to other TKIs, such as erlotinib and osimertinib6,7. Compared with standard platinum-based treatments, gefitinib has demonstrated longer progression-free survival (PFS) and improved quality of life; however, evidence regarding its impact on overall survival (OS) remains unclear8,9.  \nGefitinib acts as a reversible inhibitor of adenosine triphosphate (ATP) in the C-terminal domain of EGFR10, 11. It is typically administered at a dose of 250 mg/day, which may result in adverse drug reactions (ADRs) affecting patients’ quality of life. In some cases, it may lead to interruption or discontinuation of treatment12, 13. The most notable ADRs of gefitinib are dermatological (70–90%), gastrointestinal (39–57%), and hepatic (10%)14–17.  \nThe occurrence of ADR at a prescribed dose is dependent on several factors, such as individual characteristics (sex, age, and ethnicity), genetic factors, family history, and drug/food interactions18, 19. Individual variations in genetic traits can be explained by single-nucleotide variants (SNVs) . These variants, whether silent or not, result in changes in protein expression in individuals, affecting pharmacokinetics (PK) and pharmacodynamics and, consequently, the response to treatment20–22.  \n1Departament of Pharmacology, School of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil. 2School o","cbCaiasSBKcuLX6W","https://ap.wps.com/l/cbCaiasSBKcuLX6W","pdf",1596847,"English","# Results\n## Demographic and clinical characteristics of patients\n## ADR and survival associations","[{\"question\":\"What patient group was included in the preliminary study?\",\"answer\":\"Patients with NSCLC carrying EGFR mutations in exons 19, 20, or 21 who were treated with gefitinib 250 mg/day were included, with genetic analyses performed in 33 patients after exclusions.\"},{\"question\":\"Which genetic variant was linked to higher diarrhea risk?\",\"answer\":\"ABCB1 rs2032582 non-CC genotype was associated with a higher risk of diarrhea compared with the CC genotype.\"},{\"question\":\"What variant was associated with higher risk of death?\",\"answer\":\"The ABCB1 AA genotype was associated with a higher risk of death compared with the CA, CCCC/CA/CT, and TT genotypes.\"}]","Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients - A preliminary study | PDF",1790148428,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51f27fa7acb289461943447d4f371ee4.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eca4243712ea43a190909ca14abc29fe.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25ab2be915a2546cd8a1f6cbbe5ca9ee.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2dea7675019037c65b59614ff4b469e.webp",980,1287]